CPI

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

Retrieved on: 
Monday, April 8, 2024
Research, SOC, Conference, CPI, Ono Pharmaceutical, Patient, Standard of care, Inflammation, Pembrolizumab, IND, Investigational New Drug, WT1, Nivolumab, SITC, FDA, Autoimmunity, Annual general meeting, Pharmaceutical industry

BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, today reported fourth quarter and full year 2023 financial results.

Key Points: 
  • BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, today reported fourth quarter and full year 2023 financial results.
  • The increase was due to revenue earned from our strategic collaboration agreement entered into with Ono Pharmaceutical in the first quarter of 2023.
  • As of December 31, 2023, the Company had approximately $48.5 million in cash, cash equivalents and marketable securities compared with $76.3 million as of December 31, 2022.
  • We expect our current cash, cash equivalents, and marketable securities to fund operations into the first quarter of 2025.

CPI Aerostructures Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Saturday, April 6, 2024
EPS, CPI Aerostructures, CPI, Growth

EDGEWOOD, N.Y., April 05, 2024 (GLOBE NEWSWIRE) -- CPI Aerostructures, Inc. (“CPI Aero” or the “Company”) (NYSE American: CVU) today announced financial results for the three and twelve month periods ended December 31, 2023.

Key Points: 
  • Revenue of $86.5 million compared to $83.3 million;
    Gross profit of $17.1 million compared to $16.3 million;
    Net income of $17.2 million compared to $9.2 million;
    Cash flow from operations of $3.9 million compared to $0.9 million;
    Debt as of December 31, 2023 of $20.1 million compared to $22.8 million as of December 31, 2022.
  • EDGEWOOD, N.Y., April 05, 2024 (GLOBE NEWSWIRE) -- CPI Aerostructures, Inc. (“CPI Aero” or the “Company”) (NYSE American: CVU) today announced financial results for the three and twelve month periods ended December 31, 2023.
  • “We reported solid full-year results, delivering 3.8% increased revenue and a 4.7% increase in gross profit in 2023.
  • We generated $3.9 million in cash flow from operations during 2023, which allowed us to reduce debt by $2.7 million,” said Dorith Hakim, President and CEO.

Data Center World’s Expo Hall to Feature Hundreds of Innovative Products and Services Data Center Facilities and IT Professionals Need to Know to Plan, Manage and Optimize Data Centers

Retrieved on: 
Monday, April 8, 2024
Networks, Internet, Data Management, Technology, Software, Transfer, LTD, Transport, Carbon, HVAC, Starline, HTF, Cavitation, Virginia Transformer Corporation, Network throughput, Vertiv, MVA, Exhibition, Safety, DCIM, Fiber, Electricity, Control, Server Technology, DLC, GIGABYTE, PEAK, AI, Fluid mechanics, Network, Expo Hall, Gesellschaft mit beschränkter Haftung, Energy, GWP, Mining, Immersion, Corrosion engineering, Temperature, CPI, Hybrid, Recycling, HPC, Corrosion, Data center, DDC, Peak (automotive products), Business analyst, Dell

Data Center World , the leading global conference for data center facilities and IT professionals, will feature hundreds of innovative products and services in the Expo Hall.

Key Points: 
  • Data Center World , the leading global conference for data center facilities and IT professionals, will feature hundreds of innovative products and services in the Expo Hall.
  • The technologies will provide data center facilities and IT professionals with all the information they need to plan, manage and optimize their data centers.
  • Data Center World is AFCOM’s annual gathering of IT and data center professionals.
  • Future-proof your data center with hybrid liquid-air cooling, intelligent power handling, and enterprise environment controls by DDC’s DCIM monitoring software.

CPI Card Group® Announces Expansion with New Production Facility in Fort Wayne, Indiana

Retrieved on: 
Tuesday, April 9, 2024
Technology, Payments, Finance, Fintech, Banking, Other Technology, Professional Services, Software, Data Management, Certification, Automation, CPI, Software as a service, Digital integration, Sustainability, PMTS, Workforce, LEED, Workplace

This new facility exemplifies CPI's commitment to meeting the evolving needs of its customers and driving innovation in the payments technology industry.

Key Points: 
  • This new facility exemplifies CPI's commitment to meeting the evolving needs of its customers and driving innovation in the payments technology industry.
  • “CPI is proud to continue operating in the Fort Wayne community, where we are locally engrained with a high-performing team,” said John Lowe, President and Chief Executive Officer.
  • This is the first time in CPI’s nearly 30-year history that we’ve had the opportunity to build a manufacturing facility to our specifications.
  • Fort Wayne employees are expected to complete their transition to the new facility by early 2026.

Schwab Trading Activity Index™: Score Ascends to Moderate Levels in March

Retrieved on: 
Monday, April 8, 2024
Professional Services, Business, Finance, Fintech, Asset Management, Banking, Consumer, Education, CPI, VIX, Labour, Federal Reserve, Name, STAX, S&P, Activity, Current Population Survey, Fed, PPI, Producer, Multimedia, Treasury, Consumer confidence, CBOE, Financial adviser

The Schwab Trading Activity Index™ (STAX) increased to 51.65 in March, up from its score of 47.65 in February.

Key Points: 
  • The Schwab Trading Activity Index™ (STAX) increased to 51.65 in March, up from its score of 47.65 in February.
  • View the full release here: https://www.businesswire.com/news/home/20240408112995/en/
    Schwab Trading Activity Index March 2024 (Graphic: Charles Schwab)
    The reading for the four-week period ending March 28, 2024 ranks “moderate” compared to historic averages and marks the highest reading since May 2022.
  • “In the face of undeniably mixed macroeconomic data, the markets soared this month, and the STAX score continued its rise in step,” said Joe Mazzola, Director of Trading and Education at Charles Schwab.
  • “Despite the market highs, however, Schwab clients remain in the moderate range of market exposure as measured by the STAX.

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Friday, March 22, 2024
SIV, Clinical trial, Hepatitis, Head, CPI, Serum, Hepatitis B, Partnership, HIV, Oncology, Gilead Sciences, Patient, Lung, Journal, Viral load, Pembrolizumab, HBV, Trial of the century, IND, Infection, Hepatocyte, Arenavirus, Antibody, Vaccination, Intellectual property, FDA, Liver, Animal, Pharmaceutical industry

“It was a defining year for HOOKIPA as we witnessed the powerful potential of our novel arenaviral immunotherapies in action.

Key Points: 
  • “It was a defining year for HOOKIPA as we witnessed the powerful potential of our novel arenaviral immunotherapies in action.
  • Data was initially presented in May 2023 and additional patient data was provided in October at the European Society for Medical Oncology Congress 2023.
  • HOOKIPA expects to initiate a Phase 1 clinical study of HB-500 in people with HIV in the second quarter of 2024.
  • In June 2023, the Company completed a $50.0 million public offering of common stock and non-voting convertible preferred stock.

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Research, Combination, CPI, AML, Caregiver, Bone marrow, Insurance, Patient, Merck, Acute myeloid leukemia, Cancer, Public expenditure, Pembrolizumab, Lung cancer, Trial of the century, Cytokine release syndrome, AACR, Chemokine, Clinical trial, Annual report, Safety, Workforce, Infrared spectroscopy correlation table, NK, VISTA, Pharmaceutical industry

SEATTLE, March 21, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives, announced today financial results for the full year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • In February 2024, the Company announced a significant corporate restructuring to substantially reduce expenses and preserve cash.
  • We truly appreciate the efforts of the healthcare professionals, the patients and their caregivers, and the Kineta employees involved in this trial.
  • Announced positive KVA12123 monotherapy safety data from its ongoing Phase 1/2 VISTA-101 clinical trial in patients with advanced solid tumors.
  • Cash position: As of December 31, 2023, cash was $5.8 million, compared to $13.1 million as of December 31, 2022.

Nexus Industrial REIT Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 14, 2024
Nexus, CPI, Growth, DRIP, Class, Acquisition, Sale, News, Public expenditure, Park Street, Table, NOI, Bank statement, REIT, Analysis, Real estate

TORONTO, March 13, 2024 (GLOBE NEWSWIRE) -- Nexus Industrial REIT (the “REIT”) (TSX: NXR.UN) announced today its results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • See Appendix A of this earnings release for a reconciliation of the non-IFRS financial measures to the primary financial statement measures.
  • Acquisitions completed subsequent to October 1, 2022, generated $4.5 million of incremental NOI in Q4 2023 as compared to Q4 2022.
  • The REIT is focused on delivering total unitholder return through profitable long-term growth, and by pursing its strategy as a Canada-focused pure-play industrial REIT.
  • In the fourth quarter of 2024, the REIT expects to complete the 240,000 sq ft Dennis Rd expansion project in St Thomas, ON.

KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported

Retrieved on: 
Tuesday, March 12, 2024
Combination, CPI, Immunosuppression, Patient, Tumor microenvironment, Merck, Cancer, Pembrolizumab, Lung cancer, DLT, Merck & Co., Kineta, NK, Pharmaceutical industry

SEATTLE, March 12, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 as monotherapy and in combination with Merck’s anti-PD therapy, KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors. KVA12123 cleared the fifth of six monotherapy dose levels and the second of four cohorts in combination with pembrolizumab. KVA12123 was well tolerated with no dose limiting toxicities (DLT) or cytokine related adverse events at any dose level.

Key Points: 
  • KVA12123 cleared the fifth of six monotherapy dose levels and the second of four cohorts in combination with pembrolizumab.
  • KVA12123 was well tolerated with no dose limiting toxicities (DLT) or cytokine related adverse events at any dose level.
  • We continue to be encouraged by the safety profile of KVA12123, supporting advancement to higher doses,” said Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), to Present Data on LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Tuesday, April 2, 2024
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Shift, Principal, CPI, Drainage, Environment, Refractive surgery, ASCRS, Patient, COE, Acquisition, Faculty, Cataract, MBA, CPC, Society, Safety, Paradigm shift, Pharma, FACS, CPMA, FDA, Annual general meeting, Pharmaceutical industry

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., will be presenting data on LACRIFILL® Canalicular Gel, a novel therapy for dry eye symptoms, during the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Boston, MA on April 5-8, 2024.

Key Points: 
  • Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., will be presenting data on LACRIFILL® Canalicular Gel, a novel therapy for dry eye symptoms, during the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Boston, MA on April 5-8, 2024.
  • LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.
  • “The recent acquisition of Visant Medical along with Amring Pharmaceuticals becoming Nordic Pharma, Inc., has increased our internal know-how and assets.
  • This is where science and innovation come together, making it the perfect environment to highlight this novel therapy for dry eye.”